ENDV has to pay the Rio Grande tab, 1.5 mil, have funding to run more trials and market the Sofpulse. One of the board regulars can probably give a close estimate on what the dilution has brought in since December.
On a positive note the NHS coverage on ActiPatch begins in a couple of weeks. This should heat up the market for all PEMF wearable devices.
Market Data 
Markets 
AI
